Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
1
17%
Ph not_applicable
2
33%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(4)

Detailed Status

Completed4
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 21 (16.7%)
N/A2 (33.3%)

Trials by Status

not_yet_recruiting117%
active_not_recruiting117%
completed467%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingnot_applicable

Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

NCT07570810
active_not_recruitingphase_2

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

NCT05896137
completedphase_1

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

NCT06888115
completednot_applicable

Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

NCT06492330
completedphase_1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

NCT05624294
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07570810Not Applicable

Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

Not Yet Recruiting
NCT05896137Phase 2

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

Active Not Recruiting
NCT06888115Phase 1

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

Completed
NCT06492330Not Applicable

Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

Completed
NCT05624294Phase 1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

Completed
NCT05082779Phase 1

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6